Zyclara filed in Europe


News widgets and RSS feeds on


Thursday, 23 June 2011
The marketing authorization application for the patented product Zyclara (imiquimod 3.75% cream) has been filed with the European Medicines Agency (EMA). Zyclara has been documented for once-daily topical treatment of actinic keratosis (AK).


Zyclara expands the treatment area to the full face or balding scalp and could become a first line therapy for AK. More than 1,400 patients have been included in seven clinical studies.
“Zyclara will strengthen Meda’s dermatology franchise in Europe. We look forward to provide AK patients with a new product that can treat larger areas of the skin”, says Anders L´┐Żnner, CEO of Meda.
Based on a press release circulated by Cisionwire

Print this article

What do you think about this article? Would you like to leave a comment? It will be much appreciated. You can also rate this article.

  • Should be Empty:

Scandinavian Companies & Market Magazine
(C) 2010  Granscole Establishment Sweden AB. Registered in Sweden as a Media Company. Organisation Number: 556782-6572
F-Skatt (VAT) Number: SE556782657201